Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a primary immune system disorder that results from defective cell-to-cell signaling and disruption of inflammatory system homeostasis. This disorder usually affects children, although cases of HLH in adults have been reported (Zhang et al. 2011). HLH usually is initiated by an external stimulus, most commonly by viral infections, but familial cases have also been described (Janka 2006). Epstein-Barr virus is one of the more frequently implicated infections in the pathogenesis of HLH, but many other infections have been associated (Filipovich 2008). There are several inherited gene mutations which have been demonstrated to cause HLH. All of these genes encode proteins that participate in target-cell killing within the immune system and that effect homeostasis of the inflammatory response. Without such a regulatory system, cytokines and other inflammatory mediators are produced unchecked, resulting in fever, multiple organ system failure, pancytopenia, and death in many patients if treatment is not initiated promptly.
✠ Author was deceased at the time of publication
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Balamuth NJ, Nichols KE, Paessler M, et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007;29(8):569–73.
Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23–7.
Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376–82.
Filipovich AH. Hemophagocytic lymphohistiocytosis and other hemophagocytic disorders. Immunol Allergy Clin North Am. 2008;28(2):293–313.
Henter J-I, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.
Henter J-I, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2005;81(1):59–61.
Horne A, Trottestam H, Arico M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2008;140(3):327–35.
Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2006;166(2):95–109.
Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622–8.
Marsh RA, Vaughn G, Kim M-O, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824–31.
Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2012;60(1):101–9.
Marsh RA, Kim M-O, Liu C, et al. An intermediate Alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant. 2013;19(11):1625–31.
Rios-Fernández R, Callejas-Rubio J-L, García-Rodríguez S, Sancho J, Zubiaur M, Ortego-Centeno N. Tocilizumab as an adjuvant therapy for hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis. Am J Ther. 2015;1–4.
Sawada A, Ohga S, Ishii E, et al. Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Int J Hematol. 2013;98(2):223–30.
Tomaske M, Amon O, Bosk A, et al. α-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 2002;38(2):141–2.
Trottestam H, Horne A, Arico M, et al. Chemoimm-unotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84.
Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial hemophagocytic lymphohistiocytosis. Blood. 2011;118(22):5794–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Henry, M.M., Arceci, R.J. (2016). Hemophagocytic Lymphohistiocytosis: Diagnosis and Management Challenges. In: Abutalib, S., Connors, J., Ragni, M. (eds) Nonmalignant Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-30352-9_52
Download citation
DOI: https://doi.org/10.1007/978-3-319-30352-9_52
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30350-5
Online ISBN: 978-3-319-30352-9
eBook Packages: MedicineMedicine (R0)